Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 9/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6807473 | 0.93 | CALCRL (0.41) | CALCRLCYP3A4TNKSPARP1PARP2 | |
| SCHEMBL6803011 | 0.89 | CALCRL (0.52) | CALCRLCYP3A4HSD11B1 | |
| SCHEMBL6807774 | 0.87 | HSD11B1 (0.41) | CALCRLCYP3A4HSD11B1TNKSPARP1 | |
| SCHEMBL6807485 | 0.85 | ITGB2 (0.41) | CALCRLCYP3A4HSD11B1TNKSPARP1 | |
| SCHEMBL6807946 | 0.85 | GAA (0.44) | CYP3A4GAACYP2D6CYP2C9CYP2C19 | |
| SCHEMBL6807751 | 0.84 | CYP3A4 (0.40) | CALCRLCYP3A4GAACYP2D6CYP2C9 | |
| SCHEMBL6807625 | 0.84 | MEN1 (0.47) | CYP3A4GAACYP2D6CYP2C9CYP2C19 | |
| SCHEMBL6808040 | 0.84 | GAA (0.40) | CALCRLCYP3A4GAACYP2D6CYP2C9 | |
| SCHEMBL6808776 | 0.84 | CYP3A4 (0.43) | CALCRLCYP3A4CYP2D6 | |
| SCHEMBL6807454 | 0.83 | GAA (0.42) | CYP3A4GAACYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040039040-A1 | Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient | TORAY INDUSTRIES, INC. (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-1323709-A1 | UREA DERIVATIVE AND ADHESIVE-MOLECULE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039040-A1 | Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient | ICAM1, VCAM1, EPCAM | CALCRL 1811/4885CYP3A4 3783/4885GAA 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.